We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current PYXS market cap is 100.5M. The company's latest EPS is USD -1.2409 and P/E is -1.36.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 16.15M | 0 | 0 |
| Operating Income | -25.35M | -17.77M | -5.61M | -20.03M | -23.75M |
| Net Income | -23.05M | -15.6M | -3.26M | -17.3M | -21.2M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.88M | -12.89M | -69.72M | -123.48M | -82.2M |
| Net Income | -2.77M | -12.83M | -75.98M | -120.72M | -73.79M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 186.69M | 173.73M | 220.22M | 208.39M | 195.31M |
| Total Liabilities | 48.75M | 48.02M | 36.06M | 38.6M | 41.63M |
| Total Equity | 137.95M | 125.7M | 184.16M | 169.79M | 153.68M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 19.81M | 10.15M | 280.02M | 211.38M | 173.73M |
| Total Liabilities | 739k | 3.85M | 18.71M | 50.56M | 48.02M |
| Total Equity | -2.87M | -15.65M | 261.31M | 160.82M | 125.7M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -55.46M | -70.71M | -20.71M | -23.72M | -38.38M |
| Investing | -115.08M | -104.85M | -18.5M | -18.49M | -18.5M |
| Financing | 5.95M | 5.93M | 57.51M | 57.62M | 59.28M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -2.24M | -10.08M | -35.33M | -89.34M | -70.71M |
| Investing | N/A | -1.48M | -590k | -6.4M | -104.85M |
| Financing | 21.96M | 35k | 304.04M | 183k | 5.93M |
| Market Cap | 100.5M |
| Price to Earnings Ratio | -1.36 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 10.4 |
| Price to Book Ratio | 0.8 |
| Dividend Yield | - |
| Shares Outstanding | 59.47M |
| Average Volume (1 week) | 1.07M |
| Average Volume (1 Month) | 1.52M |
| 52 Week Change | 1.81% |
| 52 Week High | 6.85 |
| 52 Week Low | 1.49 |
| Spread (Intraday) | 0.14 (8.28%) |
| Company Name | Pyxis Oncology Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://pyxisoncology.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
